161- Chauvin A, Le Thuaut A, Belhassan M, Le Baleur Y, Mesli F, Bastuji-Garin S, et al. Infliximab
as a bridge to remission maintained by antimetabolite therapy in Crohn’s disease: a retrospec-
tive study. Dig Liver Dis. 2014;46(8):695–700. - Ordas I, Feagan BG, Sandborn WJ. Early use of immunosuppressives or TNF antagonists for
the treatment of Crohn’s disease: time for a change. Gut. 2011;60:1754–63. - Papamichael K, Vande Casteele N, Gils A, Tops S, Hauenstein S, Singh S, et al. Long-term
outcome of patients with Crohn’s disease who discontinued infliximab therapy upon clinical
remission. Clin Gastroenterol Hepatol. 2015;13(6):1103–10. - Molander P, Färkkilä M, Salminen K, Kemppainen H, Blomster T, Koskela R, et al. Outcome
after discontinuation of TNFα-blocking therapy in patients with inflammatory bowel disease
in deep remission. Inflamm Bowel Dis. 2014;20(6):1021–8. - Sorrentino D, Nash P, Viladomiu M, Hontecillas R, Bassaganya-Riera J. Stopping anti-TNF
agents in patients with Crohn’s disease in remission: is it a feasible long-term strategy?
Inflamm Bowel Dis. 2014;20(4):757–66. - Vuitton L, Marteau P, Sandborn WJ, Levesque BG, Feagan B, Vermeire S, et al. IOIBD
technical review on endoscopic indices for Crohn’s disease clinical trials. Gut. 2016;65(9):
1447–55. - Barreiro-de Acosta M, Vallejo N, De La Iglesia D, Uribarri L, Baston I, Ferreiro-Iglesias R,
et al. Evaluation of the risk of relapse in ulcerative colitis according to the degree of mucosal
healing (Mayo 0 vs 1): a longitudinal cohort study. J Crohns Colitis. 2016;10(1):13–9. - Pittet V, Froehlich F, Maillard MH, Mottet C, Gonvers JJ, Felley C, et al. When do we dare to
stop biological or immunomodulatory therapy for Crohn’s disease? Results of a multidisci-
plinary European expert panel. J Crohns Colitis. 2013;7(10):820–6. - Sorrentino D, Paviotti A, Terrosu G, Avellini C, Geraci M, Zarifi D. Low-dose maintenance
therapy with infliximab prevents postsurgical recurrence of Crohn’s disease. Clin Gastroenterol
Hepatol. 2010;8(7):591–9.e1. - Mantzaris GJ, Karatzas P, Kyriakos N, Archavlis EJ, Papamichael K, Tzannetakou X, et al.
Sa1270 can we increase the dose interval of infliximab to 10 weeks without risking loss of
response in patients with Crohn’s disease? Prospective, single-center pilot study based on suc-
cessive measurements of fecal calprotectin. Gastroenterology. 2014;146(5):S–248. - van Herwaarden N, den Broeder AA, Jacobs W, van der Maas A, Bijlsma JW, van Vollenhoven
RF, van den Bemt BJ. Down-titration and discontinuation strategies of tumor necrosis fac-
tor-blocking agents for rheumatoid arthritis in patients with low disease activity. Cochrane
Database Syst Rev. 2014;9:CD010455. - Vande Casteele N, Ferrante M, Van Assche G, Ballet V, Compernolle G, Van Steen K, et al.
Trough concentrations of infliximab guide dosing for patients with inflammatory bowel dis-
ease. Gastroenterology. 2015;148(7):1320–9.e3. - D’Haens G, Vermeire S, Lambrecht G, Baert F, Bossuyt P, Nachury M, et al. OP029 Drug-
concentration versus symptom-driven dose adaptation of Infliximab in patients with active
Crohn’s disease: a prospective, randomised, multicentre trial (Tailorix). J Crohns Colitis.
2016;10(Suppl 1):s24. - Reenaers C, Mary J-Y, Nachury M, Bouhnik Y, Laharie D, Allez M, et al. 313 Long-term out-
come after infliximab withdrawal for sustained remission in Crohn’s disease. Gastroenterology.
2016;150(4):S72. - Annunziata ML, Papparella LG, Sansoni I, Balestrieri P, Cicala M. P402 Normalized wall
thickness at MRE predicts clinical remission in Crohn’s disease after infliximab discontinua-
tion: a 5 years follow-up. J Crohns Colitis. 2014;8:S233. - Ramos L, Hernandez Camba A, Carrillo Palau M, Alonso I, Hernandez Alvarez-Buylla N,
Quintero Carrion E. P398 Outcome of treatment with biological agents in Crohn’s disease: 117
patients in 5 years from a tertiary referral center. J Crohns Colitis. 2014;8:S231. - Farkas K, Lakatos PL, Nagy F, Szepes Z, Miheller P, Papp M, et al. Predictors of relapse
in patients with ulcerative colitis in remission after one-year of infliximab therapy. Scand
J Gastroenterol. 2013;48(12):1394–8.
10 Cessation of Biologics: Can It Be Done?